Exclusive Online Content
NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
LAGUNA HILLS, Calif., July 30, 2015 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from…
Unilife Introduces World's First Instant Patch Pump for Insulin
York, PA. – July 29, 2015. Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery…
Xcelience Makes Structured Cash Investment in Powdersize
TAMPA, FLORIDA (July 31, 2015) – Xcelience, a contract development and manufacturing organization (CDMO), recently announced that it has made a structured cash investment in…
Pharma, Medical & Biotech Global Trend Report
Mergermarket has released its Global Pharma, Medical & Biotech (PMB) trend report for the first half (H1) of 2015. Take a look at the…
Vetter Launches Vetter-Ject® - A New Syringe Closure System for Highly Sensitive Compounds
Vetter recently announced the release of Vetter-Ject®, a novel closure system for prefilled syringes. By this closure part a baked-in siliconization of an integrated needle…
Ludwig Cancer Research & University of Oxford Launch Cancer Immunotherapy Spinout
Isis Innovation, the University of Oxford’s technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, iOx…
Exostar's Identity Hubs - Making Security a Business Enabler Throughout the Drug Development Process
With a price tag north of $1B and a duration in the neighborhood of a decade, the drug development process costs too much and takes…
“Biomaterial of the Future” Nanocellulose to Send Market Booming with 42.8% CAGR
Nanocellulose (NC) is quickly becoming commercially available worldwide, and the production capacity is increasing exponentially. BCC Research reveals in its new report, Cellulose Nanoparticles: Processing,…
Exostar & Taigle Partnership Delivers Solutions to Life Science & Healthcare Markets
Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Taigle mySignatureBook, a leading digital workflow provider in the…
Global Biosimilars Market Value Could Hit $55 Billion
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth…
Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined…
Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies…
PlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease Commitment
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, recently…
SIGNiX & Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science & Healthcare
Researchers, Clinical Trial Participants, Physicians and Others Can Access Cloud-Based Independent E-Signatures™ via the Exostar Life Sciences Identity Hub CHATTANOOGA, Tenn., June 18, 2015 –…
Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform
Emulate, Inc. recently announced that it recently formed a research collaboration with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson (Janssen), to…
Pancreatic Cancer Treatment Pipeline Dominated by Early Stage Development
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the…
Ajinomoto Althea Receives European GMP Certification for Commercial Aseptic Filling & Testing
Ajinomoto Althea, Inc. (Althea), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate…
Trehalose: A Powerful Excipient in the Formulation Toolbox
By: Ben Nelson, PhD, and Chris Wilcox (inquiries to: cs@pfanstiehl.com) Trehalose is a non-reducing disaccharide consisting of two glucose molecules linked by an α,α–1,1…
BIND Therapeutics & Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform
BIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables…
Targeted Therapeutics & Nanoparticles
A key objective of pharmaceutical and biopharmaceutical development is to increase product therapeutic specificity and safety. Some of the recent exciting developments have obviously been…